CCO Jeff Evanson exits Outlook Therapeutics (NASDAQ: OTLK) role

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. reported that Chief Commercial Officer Jeff Evanson stepped down from his role effective September 5, 2025. His departure is treated as a termination of employment without “cause” under his executive employment agreement and other company plans. Subject to his signing and not revoking a separation agreement that includes a release of claims against the company, he will receive severance benefits consistent with the terms provided for a termination without cause. The company states that a description of these severance benefits is contained in its Definitive Proxy Statement filed on February 10, 2025, which is incorporated by reference.

Insights

Corporate governance and executive compensation analyst

Outlook Therapeutics’ CCO exits, triggering standard no-cause severance terms.

The company states that Chief Commercial Officer Jeff Evanson has stepped down effective September 5, 2025, and that his departure is classified as a termination without “cause.” This framing matters because it determines which contractual protections in his employment and equity agreements apply, including eligibility for severance.

The severance package will follow the existing executive employment agreement, contingent on his executing and not revoking a separation agreement with a release of claims. The economic and equity impact is therefore governed by terms already disclosed in the February 10, 2025 definitive proxy statement, rather than any newly negotiated arrangement. Investors can use that prior disclosure to understand the scale and form of benefits tied to this leadership change.

false 0001649989 0001649989 2025-09-05 2025-09-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 5, 2025

Outlook Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37759	38-3982704
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

111 S. Wood Avenue, Unit #100 Iselin, New Jersey	08830
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (609) 619-3990

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12 (b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		OTLK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Commercial Officer

On September 5, 2025, Mr. Jeff Evanson stepped down as the Chief Commercial Officer of Outlook Therapeutics, Inc. (the “Company”), effective immediately (the “Effective Date”).

Mr. Evanson’s departure constitutes a termination of employment without “cause” for purposes of any employment, equity compensation or benefit agreement, plan or arrangement of the Company and its subsidiaries to which Mr. Evanson is a party or otherwise participates, including that certain executive employment agreement, dated as of December 21, 2021, by and between Mr. Evanson and the Company (the “Employment Agreement”). Accordingly, subject to Mr. Evanson’s execution and non-revocation of a separation agreement containing a release of claims against the Company, Mr. Evanson will receive severance benefits consistent with the Employment Agreement for a termination of employment without “cause.” A description of Mr. Evanson’s severance benefits is set forth in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on February 10, 2025, and is incorporated by reference herein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Outlook Therapeutics, Inc.
Date: September 5, 2025	By:	/s/ Lawrence A. Kenyon
		Lawrence A. Kenyon
		Interim Chief Executive Officer

FAQ

What did Outlook Therapeutics (OTLK) announce in this Form 8-K?

Outlook Therapeutics announced that Chief Commercial Officer Jeff Evanson stepped down from his position, effective September 5, 2025, and is being treated as terminated without cause under his existing agreements.

How is Jeff Evanson’s departure from Outlook Therapeutics (OTLK) classified?

The company states that Mr. Evanson’s departure is a termination of employment without “cause” for purposes of all relevant employment, equity compensation, and benefit arrangements.

Will Outlook Therapeutics’ former CCO receive severance benefits?

Yes. Subject to his execution and non-revocation of a separation agreement that includes a release of claims, Mr. Evanson will receive severance benefits consistent with his employment agreement’s terms for a termination without cause.

Where are the details of the severance for Outlook Therapeutics’ CCO disclosed?

The company states that a description of Mr. Evanson’s severance benefits is provided in its Definitive Proxy Statement on Schedule 14A filed with the SEC on February 10, 2025, which is incorporated by reference.

Who signed the Outlook Therapeutics (OTLK) report about the CCO’s departure?

The report was signed on behalf of Outlook Therapeutics, Inc. by Lawrence A. Kenyon, identified as the company’s Interim Chief Executive Officer.

Does the Outlook Therapeutics 8-K mention any changes to Mr. Evanson’s existing agreements?

The company refers to Mr. Evanson’s existing executive employment agreement dated December 21, 2021 and states that severance will be provided consistent with that agreement for a termination without cause, rather than describing new terms.